Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.
June 9, 2026 - 14:51
By Pharos Investment Advisors Comments are Off
Britain’s second-largest drugmaker GSK has entered an agreement to acquire U.S.-based drugmaker Nuvalent for $10.6 billion to bolster its oncology pipeline, in what would be its largest acquisition in more than a decade.
Regulated by Hellenic Capital Market Commission
with Registration Number 5/700/10.12.2014

Copyright 2023©. All Rights Reserved